Compare RS & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RS | INAB |
|---|---|---|
| Founded | 1939 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.4B | 22.9M |
| IPO Year | 1996 | 2020 |
| Metric | RS | INAB |
|---|---|---|
| Price | $299.29 | $1.89 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $324.33 | $6.00 |
| AVG Volume (30 Days) | ★ 352.8K | 34.5K |
| Earning Date | 05-21-2026 | 06-23-2026 |
| Dividend Yield | ★ 1.68% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 13.98 | N/A |
| Revenue | ★ $14,805,900,000.00 | N/A |
| Revenue This Year | $8.85 | N/A |
| Revenue Next Year | $1.03 | N/A |
| P/E Ratio | $21.40 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $250.07 | $0.12 |
| 52 Week High | $365.59 | $4.20 |
| Indicator | RS | INAB |
|---|---|---|
| Relative Strength Index (RSI) | 36.46 | 54.96 |
| Support Level | $283.39 | $1.52 |
| Resistance Level | $301.60 | $2.15 |
| Average True Range (ATR) | 8.46 | 0.16 |
| MACD | -1.77 | 0.05 |
| Stochastic Oscillator | 15.66 | 67.65 |
Reliance Inc operates a network of companies providing diversified metal solutions and is the metals service center company. It distributes a full line of over 100,000 metal products, including alloy, aluminum, brass, copper, carbon steel, stainless steel, titanium and other specialty steel products. The company services more than 125,000 customers in a variety of industries, including consumer products, general manufacturing, non-residential construction, transportation, aerospace, energy, electronics and semiconductor fabrication, industrial machinery and heavy industry. It also services the auto industry, through its toll processing operations where it processes customer-owned metal for a fee.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.